ISN Webinar: Semaglutide’s Impact on Kidney Disease and Cardiovascular Outcomes in Type 2 Diabetes: Insights from the FLOW Study
- 06:00 PM EDT
Join us for an insightful webinar hosted by the International Society of Nephrology (ISN) focusing on the recent results from the phase FLOW trial, which evaluated the effects of semaglutide on kidney disease and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD).
The FLOW trial (ClinicalTrials.gov Identifier: NCT03819153) was a randomized, double-blind, parallel-group, placebo-controlled study involving 3533 participants with type 2 diabetes and CKD. The trial assessed the effects of semaglutide 1mg compared to placebo on kidney outcomes, including progression of renal impairment and risk of renal and cardiovascular mortality.Key results showed that treatment with semaglutide 1mg significantly reduced the risk of kidney disease progression, cardiovascular events, and mortality by 24% compared with placebo. These findings underscore the potential of semaglutide to become the first GLP-1 receptor agonist treatment option for individuals with type 2 diabetes and CKD.
Dr. Katherine Tuttle and Dr. Vlado Perkovic, esteemed nephrology experts, will delve into the major efficacy outcomes, including the time to first occurrence of a composite primary endpoint event, the impact on eGFR, and the reduction in major adverse cardiovascular events and all-cause mortality.
Learning objectives:
- To present the key findings of the FLOW trial, highlighting the significant reduction in kidney disease-related events with semaglutide treatment.
- To discuss the implications of these findings for clinical practice, particularly for the management of patients with type 2 diabetes and CKD.
- To explore the potential for semaglutide as a novel GLP-1 treatment option for this patient population.
Moderator
Roberto Pecoits-Filho (USA)
Speakers
Katherine Tuttle (USA)
Vlado Perkovic (Australia)